Patents by Inventor Wayne R. Kindsvogel

Wayne R. Kindsvogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING IL-TIF ASSOCIATED INFLAMMATORY OR IMMUNE DISEASES USING ANTIBODIES AGAINST SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS
    Publication number: 20130028894
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 31, 2013
    Applicant: ZYMOGENETICS, INC.
    Inventors: Wayne R. KINDSVOGEL, Stavros TOPOUZIS
  • Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
    Patent number: 8361954
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: January 29, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
  • METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS
    Publication number: 20130022571
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 24, 2013
    Inventors: Kevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E. Henderson
  • Use of IL-29 for treating a dengue virus infection
    Patent number: 8318147
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: November 27, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Kevin M. Klucher, Pallavur V Sivakumar, Wayne R Kindsvogel, Katherine E Henderson
  • Compositions and methods for antibody and ligand identification
    Publication number: 20120282246
    Abstract: Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 8, 2012
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • Compositions and methods for antibody and ligand identification
    Publication number: 20120283143
    Abstract: Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 8, 2012
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • Compositions and methods for antibody and ligand identification
    Publication number: 20120283113
    Abstract: Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
    Type: Application
    Filed: May 6, 2011
    Publication date: November 8, 2012
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors
    Patent number: 8287866
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: October 16, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Stavros Topouzis
  • Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
    Patent number: 8283448
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: October 9, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Kevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E Henderson
  • METHODS OF TREATMENT USING ANTI-IL-22RA ANTIBODIES
    Publication number: 20120156210
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: January 12, 2012
    Publication date: June 21, 2012
    Applicant: ZYMOGENETICS, INC.
    Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
  • Non-external static magnetic field imaging systems, devices, methods, and compositions
    Patent number: 8154285
    Abstract: Magnetic resonance systems, devices, methods, and compositions are provided. Further provided are systems, devices, methods, and compositions for obtaining magnetic resonance information of a region within a biological subject without the need or use of an external-magnet.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: April 10, 2012
    Inventors: Roderick A. Hyde, Jordin T. Kare, Wayne R. Kindsvogel
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20120082673
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: November 3, 2011
    Publication date: April 5, 2012
    Inventors: Scott R. PRESNELL, Wenfeng XU, Wayne R. KINDSVOGEL, Zhi CHEN, Steven D. HUGHES
  • Ingestible salt grabber
    Publication number: 20120070380
    Abstract: Disclosed herein include embodiments related to compositions, devices, computer systems, computer-implemented methods, and computer program products associated with an ingestible salt grabber.
    Type: Application
    Filed: September 21, 2010
    Publication date: March 22, 2012
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight, Lowell L. Wood, JR.
  • ZCYTOR19 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS
    Publication number: 20120053321
    Abstract: Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: October 4, 2011
    Publication date: March 1, 2012
    Inventors: Wenfeng Xu, Stacy Schlutsmeyer, Cameron S. Brandt, Wayne R. Kindsvogel, Katherine E. Henderson, Theodore E. Whitmore, Kevin M. Klucher
  • Methods of treatment using anti-IL-22RA antibodies
    Patent number: 8124088
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
  • Artificial cells
    Publication number: 20120034155
    Abstract: The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.
    Type: Application
    Filed: August 3, 2010
    Publication date: February 9, 2012
    Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Wayne R. Kindsvogel, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • Multiplex imaging systems, devices, methods, and compositions including ferromagnetic structures
    Patent number: 8106655
    Abstract: Multiplex imaging systems, devices, methods, and compositions are provided. A nuclear magnetic resonance imaging composition includes, but is not limited to, a plurality of ferromagnetic microstructures configured to generate a time-invariant magnetic field within at least a portion of one or more internal surface-defined voids.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: January 31, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Jordin T. Kare, Wayne R. Kindsvogel
  • MHC-Less cells
    Publication number: 20120020885
    Abstract: The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.
    Type: Application
    Filed: August 9, 2010
    Publication date: January 26, 2012
    Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, Wayne R. Kindsvogel, Eric C. Leuthardt, Stephen L. Malaska, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • MHC-Less cells
    Publication number: 20120020987
    Abstract: The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.
    Type: Application
    Filed: July 26, 2010
    Publication date: January 26, 2012
    Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, Wayne R. Kindsvogel, Eric C. Leuthardt, Stephen L. Malaska, Gary L. McKnight, Elizabeth A. Sweeney, Lowell L. Wood, JR.
  • METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29
    Publication number: 20120020919
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Application
    Filed: September 6, 2011
    Publication date: January 26, 2012
    Inventors: Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson